Neurocrine Biosciences (NBIX)
Develops and commercializes neuroscience and rare-disease medicines led by INGREZZA.
$142.53
vs last close−1.44 (−1.00%)
Something off on this page? Send us feedback.
Next report
Oct 27, 26
in 35 days
EPS estimate
$2.59
Revenue estimate
$1.04B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Jul '25Oct '25Feb '26May '26Jul '26Oct '26
Reported$1.00$0.08$1.06$2.04$1.88$1.94$1.39Pending
Estimate$1.62$0.54$0.98$1.58$1.80$1.22$1.65$2.59
Surprise−38.3%−85.0%+8.2%+29.1%+4.4%+59.0%−15.8%—
RevenueReportedEstimate
Feb '25May '25Jul '25Oct '25Feb '26May '26Jul '26Oct '26
Reported$627.7M$572.6M$687.5M$794.9M$805.5M$814.5M$959.0MPending
Estimate$629.4M$559.6M$746.4M$806.8M$790.5M$768.3M$891.2M$1.04B
Surprise−0.3%+2.3%−7.9%−1.5%+1.9%+6.0%+7.6%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $5.93 | — | — |
| Sep 2028 | $5.74 | — | — |
| Jun 2028 | $5.59 | — | — |
| Mar 2028 | $5.20 | — | — |
| Dec 2027 | $3.00 | — | — |
| Sep 2027 | $2.67 | — | — |
| Jun 2027 | $2.48 | — | — |
| Mar 2027 | $2.59 | — | — |
| Dec 2026 | $1.85 | — | — |
| Oct 2026 | $2.59 | — | — |
| Jul 2026 | $1.65 | $1.39 | −15.8% |
| May 2026 | $1.22 | $1.94 | +59.0% |
| Feb 2026 | $1.80 | $1.88 | +4.4% |
| Oct 2025 | $1.58 | $2.04 | +29.1% |
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $5.93 | — | — | $1.53B | — | — | — |
| Sep 2028 | $5.74 | — | — | $1.50B | — | — | — |
| Jun 2028 | $5.59 | — | — | $1.46B | — | — | — |
| Mar 2028 | $5.20 | — | — | $1.42B | — | — | — |
| Dec 2027 | $3.00 | — | — | $1.21B | — | — | — |
| Sep 2027 | $2.67 | — | — | $1.18B | — | — | — |
| Jun 2027 | $2.48 | — | — | $1.14B | — | — | — |
| Mar 2027 | $2.59 | — | — | $1.11B | — | — | — |
| Dec 2026 | $1.85 | — | — | $1.08B | — | — | — |
| Oct 27, 2026 | $2.59 | — | — | $1.04B | — | — | — |
| Jul 30, 2026 | $1.65 | $1.39 | −15.8% | $891.2M | $959.0M | +7.6% | −10.1% |
| May 5, 2026 | $1.22 | $1.94 | +59.0% | $768.3M | $814.5M | +6.0% | +8.9% |
| Feb 11, 2026 | $1.80 | $1.88 | +4.4% | $790.5M | $805.5M | +1.9% | −10.4% |
| Oct 28, 2025 | $1.58 | $2.04 | +29.1% | $806.8M | $794.9M | −1.5% | −6.4% |
| Jul 30, 2025 | |||||||
| May 5, 2025 | |||||||
| Feb 6, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 1, 2024 | |||||||
| Feb 7, 2024 | |||||||
| Oct 31, 2023 | |||||||
| Aug 1, 2023 | |||||||
| May 3, 2023 | |||||||
| Feb 6, 2023 | |||||||
| Nov 1, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 4, 2022 | |||||||
| Feb 11, 2022 | |||||||
| Nov 1, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 5, 2021 | |||||||
| Feb 4, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 3, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 4, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Jul 29, 2019 | |||||||
| Apr 29, 2019 | |||||||
| Feb 5, 2019 | |||||||
| Nov 5, 2018 | |||||||
| Jul 31, 2018 | |||||||
| Apr 30, 2018 | |||||||
| Feb 13, 2018 | |||||||
| Nov 1, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 9, 2017 | |||||||
| Feb 14, 2017 | |||||||
| Nov 2, 2016 | |||||||
| Aug 3, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 11, 2016 | |||||||
| Oct 29, 2015 | |||||||
| Jul 29, 2015 |